Premium
Experiences and perspectives of cancer stakeholders regarding COVID‐19 vaccination
Author(s) -
Bartley Nicci,
Havard Polly,
Butow Phyllis,
Shaw Joanne
Publication year - 2023
Publication title -
asia‐pacific journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 29
eISSN - 1743-7563
pISSN - 1743-7555
DOI - 10.1111/ajco.13808
Subject(s) - vaccination , context (archaeology) , stakeholder , medicine , family medicine , cancer , population , public relations , immunology , environmental health , political science , paleontology , biology
Aim The risk of dying from COVID‐19 is higher for those who are older, immune‐compromised, or chronically ill. Vaccines are an effective strategy in reducing mortality and morbidity from COVID‐19. However, for COVID‐19 vaccination programs to reach full potential, vaccines must be taken up by those at greatest risk, such as cancer patients. Understanding the perspectives of all stakeholders involved in cancer patient COVID‐19 vaccine uptake will be critical to ensuring appropriate support, and information is provided to facilitate vaccination. The aim of this research was to explore the longitudinal views of cancer stakeholders regarding COVID‐19 vaccination. Methods Semistructured interviews were conducted with cancer patients ( n = 23), family members ( n = 10), cancer health professionals ( n = 19), and representatives of cancer nongovernment organizations ( n = 7) across Australia 6 and 12 months postrecruitment. Transcripts were thematically analyzed, using an inductive approach. Results All stakeholder groups expressed mostly positive attitudes toward COVID‐19 vaccination, with the following key themes identified: (1) high motivation—vaccination perceived as offering health protection and hope; (2) hesitancy—concern about vaccine hesitancy among the general population, with a minority hesitant themselves; (3) confusion and frustration—regarding the vaccine rollout and patient eligibility; (4) uncertainty—about vaccination in the context of cancer; (5) access to vaccination; and (6) desire for expert individualized advice—on vaccine interaction with cancer treatments. Conclusion These findings highlight the COVID‐19 vaccine concerns and information needs of cancer stakeholders. Policymakers need to provide clear tailored information regarding vaccine eligibility, accessibility, benefits, and risks to facilitate vaccine uptake.